Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial

Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial

Submitted by admin on March 9, 2023 - 10:00am
Source: 
Endpoints
News Tags: 
AstraZeneca
lung cancer
clinical trials
Tagrisso
Headline: 
Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial
snippet: 

AstraZeneca put out word Thursday morning that its lung cancer therapy and EGFR inhibitor Tagrisso met a secondary endpoint of overall survival in a Phase III trial.

Do Not Allow Advertisers to Use My Personal information